List of Excipients in Branded Drug GIVLAARI

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Alnylam Pharmaceuticals Inc	GIVLAARI	givosiran sodium	71336-1001	WATER	2026-11-20

GIVLAARI Excipient Strategy and Commercial Opportunities

Last updated: August 18, 2026

GIVLAARI (givosiran) is a subcutaneous, sterile RNA interference drug with a deliberately simple excipient system: water for injection, sodium hydroxide, and phosphoric acid. The commercial opportunity is therefore concentrated in high-quality excipient supply, sterile fill-finish, container-closure systems, formulation optimization, and lifecycle-management technologies rather than in a broad platform of novel excipients. GIVLAARI has no biosimilar pathway, and conventional generic substitution is difficult because it is a chemically defined siRNA conjugate administered by injection.

What excipients are used in GIVLAARI?

GIVLAARI is supplied as a sterile, preservative-free solution for subcutaneous use. The FDA-approved formulation contains:

Component	Function
Givosiran sodium	Active siRNA conjugate
Water for injection	Primary solvent
Sodium hydroxide	pH adjustment
Phosphoric acid	pH adjustment and buffering contribution

The product is supplied in a single-dose vial. The formulation is administered by a healthcare professional at a recommended dose of 2.5 mg/kg once monthly. The label identifies the product as a clear, colorless-to-yellow solution suitable for subcutaneous injection.[1]

The limited excipient composition reduces formulation complexity but increases the importance of control over pH, osmolality, particulate matter, extractables, leachables, sterility, and container-closure performance. For a high-value orphan injectable, excipient quality can affect batch release, supply continuity, and regulatory comparability even when the excipients themselves are conventional.

Why does GIVLAARI use a minimal excipient system?

The formulation reflects the properties of an siRNA conjugate rather than the requirements of a conventional small-molecule solution.

Givosiran is a GalNAc-conjugated, double-stranded siRNA designed to silence hepatic ALAS1 mRNA. The GalNAc ligand enables uptake through the asialoglycoprotein receptor on hepatocytes, allowing subcutaneous administration at a monthly interval.[2] The product does not require lipid nanoparticles, a co-solvent system, or a complex surfactant package.

A minimal aqueous formulation provides several commercial and regulatory advantages:

1. It limits the number of raw materials subject to supplier qualification.
2. It reduces the number of potential degradation pathways.
3. It simplifies analytical characterization and batch release.
4. It lowers the risk of excipient-related immunogenicity or local tolerability problems.
5. It supports a conventional sterile vial presentation.

The tradeoff is that there are fewer obvious opportunities to differentiate the product through excipient substitution. Any change to the formulation would need to demonstrate that it preserves siRNA integrity, conjugate stability, potency, sterility, injection performance, and clinical tolerability.

What is the excipient supply-chain opportunity for GIVLAARI?

The strongest near-term opportunities are in regulated commodity supply rather than new chemical entities.

Water for injection

Water for injection is the highest-volume formulation component and must meet applicable United States Pharmacopeia and manufacturing requirements. Commercial opportunities include:

• validated WFI supply for sterile manufacturing;
• generation and distribution systems;
• microbial and endotoxin control;
• continuous monitoring;
• backup supply qualification;
• regional manufacturing redundancy.

WFI is not a differentiated product in the ordinary sense. Its value is linked to compliance, reliability, and integration with sterile manufacturing operations.

Sodium hydroxide and phosphoric acid

Sodium hydroxide and phosphoric acid are used for pH control. Their technical value depends on:

• pharmaceutical-grade quality;
• low metal content;
• low bioburden and endotoxin levels;
• consistent concentration;
• validated sterilization or sterile filtration compatibility;
• documented change-control procedures.

A supplier that can provide prequalified, low-volume sterile-grade materials with strong regulatory documentation may have more commercial leverage than a lower-cost commodity supplier.

Vial, stopper, and seal systems

For an injectable product, container-closure performance can be more commercially important than the chemical excipients. Relevant opportunities include:

• low-extractables glass vials;
• elastomeric stoppers compatible with aqueous oligonucleotide solutions;
• aluminum seals and crimp systems;
• siliconization control;
• container-closure integrity testing;
• particulate reduction;
• cold-chain and shipping validation.

Packaging suppliers can create defensible value by demonstrating long-term compatibility with the formulation and by supporting regulatory submissions with extractables, leachables, and stability data.

What formulation characteristics create commercial opportunities?

GIVLAARI’s formulation is commercially attractive because it is simple, but the active ingredient is technically demanding. The main development constraints are likely to involve the givosiran conjugate, not conventional excipients.

Stability

Potential stability risks include:

• hydrolysis of phosphodiester linkages;
• degradation of modified nucleotides;
• loss of GalNAc conjugate integrity;
• aggregation or subvisible particle formation;
• adsorption to manufacturing surfaces;
• pH-driven degradation;
• freeze-thaw sensitivity.

A formulation supplier or contract development organization could create value through low-binding process-contact materials, optimized sterile filtration, improved vial systems, or alternative storage conditions.

Injection performance

The product is administered subcutaneously, which places practical limits on:

• injection volume;
• viscosity;
• osmolality;
• pH;
• local tissue tolerability;
• syringeability;
• needle force.

The monthly dosing schedule reduces administration frequency, but the product remains dependent on reliable subcutaneous delivery in a clinical setting.

Preservative-free presentation

The single-dose, preservative-free format limits multidose contamination risk and avoids preservative-related tolerability concerns. It also creates demand for:

• highly reliable single-dose packaging;
• low-particulate manufacturing;
• robust stopper reseal and closure performance;
• efficient aseptic fill-finish.

A multidose presentation could reduce packaging cost in some settings, but it would introduce preservative, microbial-control, and regulatory complexities. It is not an obvious improvement without evidence of clinical or economic benefit.

What alternative excipients could support a GIVLAARI lifecycle strategy?

Potential formulation-development directions include alternative buffering systems, tonicity agents, surfactants, and lyophilization. Each has material technical and regulatory constraints.

Strategy	Potential benefit	Principal risk
Histidine buffer	May improve pH control and stability	New degradation and compatibility profile
Citrate buffer	Established injectable excipient	Possible local tolerability and metal-interaction concerns
Tonicity agent	Improved injection comfort or osmolality control	Added impurity and stability burden
Polysorbate or other surfactant	Reduced adsorption or aggregation	Peroxide, particle, and degradation risks
Lyophilized cake	Potentially improved long-term stability	Reconstitution burden and new device requirements
Prefilled syringe	Administration convenience	Silicone, glide force, and container-closure issues
Autoinjector	Potential home-use opportunity	Volume, viscosity, dose accuracy, and human-factors requirements

A formulation change would not automatically create a marketable product. For an approved orphan injectable, the commercial case would need to justify the development cost against a limited patient population and an already established monthly dosing regimen.

What patents protect GIVLAARI and its formulation?

The core GIVLAARI intellectual property is expected to center on givosiran’s siRNA sequence, chemical modifications, conjugation architecture, target gene silencing, pharmaceutical compositions, and therapeutic uses. The relevant rights may be held across multiple patent families rather than in a single formulation patent.

The main patent categories are:

Active ingredient and sequence patents

These may cover:

• specific antisense and sense strand sequences;
• nucleotide modifications;
• double-stranded siRNA structures;
• GalNAc conjugation;
• linker chemistry;
• targeting of ALAS1 or related hepatic pathways.

These rights are more strategically important than the sodium hydroxide, phosphoric acid, and WFI formulation because they can block development of a competing givosiran product even if the competitor uses different excipients.

Pharmaceutical composition patents

Composition claims may cover:

• givosiran or related conjugates in aqueous solution;
• concentration ranges;
• pH ranges;
• salts;
• stabilizing systems;
• injectable formulations;
• storage conditions.

A competitor using the same active ingredient but a different excipient system would need to assess whether its product falls within any composition claims.

Method-of-use patents

Potential method-of-use coverage may relate to:

• treatment of acute hepatic porphyria;
• reduction of urinary aminolevulinic acid and porphobilinogen;
• prevention or reduction of porphyria attacks;
• dosing schedules;
• patient populations;
• long-term administration.

Method-of-use patents can remain commercially relevant after core composition rights expire, particularly where the product has multiple dosing regimens or patient subgroups.

Manufacturing and process patents

These may cover:

• synthesis of modified oligonucleotides;
• conjugation processes;
• purification;
• impurity removal;
• sterile processing;
• formulation and filling.

Manufacturing rights can create practical barriers even where a competing company has designed around composition claims.

The FDA Orange Book, USPTO records, and relevant patent litigation dockets should be treated as the controlling sources for current listed patents, expiration dates, terminal disclaimers, patent-term adjustment, and any pediatric extensions.[3,4]

When does GIVLAARI lose exclusivity?

GIVLAARI received FDA approval on November 20, 2019, for adults with acute hepatic porphyria.[1] As an orphan drug, it received seven years of FDA orphan-drug exclusivity, subject to the statutory exceptions for clinical superiority and other regulatory circumstances. The principal orphan exclusivity period therefore runs to November 20, 2026.

Orphan exclusivity does not eliminate patent protection. It also does not prevent all forms of competition. A competitor may pursue a legally distinct indication, challenge patents, or use a different regulatory pathway where permitted.

The commercial loss-of-exclusivity timeline should be analyzed across four separate dates:

Exclusivity layer	Relevance
FDA orphan exclusivity	Blocks approval of the same drug for the same disease or condition during the statutory period
Listed patents	May block or delay an ANDA or other competing product
Regulatory data protections	May affect reliance on FDA data, depending on the pathway
Trade secrets and manufacturing know-how	May increase development cost without creating a public approval bar

There is no biosimilar-style automatic expiration date for GIVLAARI because givosiran is not a biologic regulated through the biosimilar pathway.

Is GIVLAARI exposed to generic or biosimilar competition?

GIVLAARI has limited conventional generic risk and no conventional biosimilar risk.

505(j) generic risk

An ANDA applicant would need to demonstrate pharmaceutical equivalence and bioequivalence to a chemically complex injectable siRNA product. The active ingredient is not a simple small molecule. Differences in strand sequence, nucleotide modification, conjugation, impurities, particle profile, or biological activity could prevent a straightforward generic showing.

A conventional ANDA remains legally possible only if the applicant can satisfy FDA requirements for the reference product. The technical burden is likely to be higher than for a standard aqueous small-molecule injection.

505(b)(2) risk

A 505(b)(2) applicant could pursue a modified product using some reliance on FDA findings for GIVLAARI while introducing a different formulation, presentation, dosing approach, or delivery system. The principal opportunities would be:

• prefilled syringe presentation;
• autoinjector or assisted injection;
• improved storage conditions;
• altered concentration;
• reduced injection volume;
• new patient population;
• differentiated administration setting.

A 505(b)(2) product would still face patent certifications, clinical bridging requirements, analytical comparability issues, and commercial access barriers.

Biosimilar risk

Biosimilar competition is not the relevant framework. Givosiran is an oligonucleotide drug, not a protein biologic. The competitive threat is more likely to come from follow-on oligonucleotide products, alternative RNAi therapies, or new treatments for acute hepatic porphyria.

What Paragraph IV challenges and litigation affect GIVLAARI?

A Paragraph IV challenge would be the most visible pathway for an ANDA applicant seeking to enter before patent expiry. The applicant would need to certify that listed patents are invalid, unenforceable, or not infringed.

The key litigation questions would be:

• whether any GIVLAARI patents are listed in the Orange Book;
• whether the challenged claims cover the active conjugate, formulation, or use;
• whether the ANDA product uses the same sequence and conjugation architecture;
• whether a 30-month stay is triggered;
• whether the parties enter a launch-date settlement;
• whether a covenant not to sue or license affects entry.

No confirmed Paragraph IV litigation or public settlement should be assumed without a current review of FDA Orange Book records, court dockets, and company disclosures. The absence of identified litigation in the cited sources is not equivalent to freedom from future challenge.

What licensing deals support GIVLAARI commercial opportunities?

Givosiran originated within Alnylam’s RNAi platform. The principal commercial rights are associated with Alnylam Pharmaceuticals, which developed and markets GIVLAARI.[1,5]

The relevant licensing analysis is therefore less about excipient licensing and more about platform control. A competitor would need to consider rights relating to:

• GalNAc conjugation;
• chemically modified siRNA;
• hepatic delivery;
• ALAS1 silencing;
• manufacturing technologies;
• patent cross-licenses;
• third-party oligonucleotide chemistry.

Excipient suppliers generally do not need a license to sell standard pharmacopeial materials. A license may become relevant if a supplier commercializes a proprietary stabilizer, novel conjugate excipient, specialized delivery component, or patented container-closure technology.

How strong is the GIVLAARI patent estate?

The estate is strategically stronger at the active-ingredient and platform levels than at the conventional excipient level.

Patent layer	Strategic strength
Givosiran sequence and conjugate	High, because design-around may require a different active molecule
GalNAc delivery architecture	Potentially high, depending on claim scope and remaining term
ALAS1 method of use	Moderate to high for the approved indication
Aqueous injectable formulation	Variable; depends on claim breadth and prior art
WFI, sodium hydroxide, phosphoric acid	Low as standalone barriers
Manufacturing process	Potentially high if difficult to replicate
Container closure	Moderate, usually design-around possible

The most important freedom-to-operate issue is whether a follow-on product can use the same therapeutic mechanism without practicing protected sequence, conjugation, or manufacturing claims. Changing excipients alone may not avoid infringement.

What commercial opportunities exist for excipient and formulation suppliers?

The opportunity set is concentrated in five areas.

Qualified raw-material supply

Suppliers can compete on:

• sterile-grade phosphoric acid and sodium hydroxide;
• low-metal and low-endotoxin specifications;
• dual sourcing;
• regional supply;
• audit readiness;
• change-control discipline.

Sterile fill-finish

Contract manufacturers can offer value through:

• low-volume biologic and oligonucleotide filling;
• aseptic vial filling;
• nitrogen management where applicable;
• low-binding equipment;
• particulate control;
• validated cold-chain handling;
• stability-indicating release testing.

Container-closure systems

Packaging companies can target:

• low-extractables elastomers;
• coated stoppers;
• ready-to-use vials;
• prefilled syringe systems;
• low-silicone delivery components;
• container-closure integrity programs.

Reformulation and lifecycle management

Potential projects include:

• reducing injection volume;
• moving to a prefilled syringe;
• enabling home administration;
• extending refrigerated shelf life;
• improving freeze-thaw tolerance;
• developing a concentrated formulation;
• creating a less burdensome presentation for chronic monthly use.

Analytical and regulatory services

Specialized service providers can support:

• siRNA integrity testing;
• conjugate-content analysis;
• impurity profiling;
• potency assays;
• subvisible particle testing;
• extractables and leachables;
• comparability protocols;
• stability modeling.

These services may be commercially attractive because analytical methods for oligonucleotide conjugates are more specialized than routine excipient testing.

How does GIVLAARI compare with competing RNAi products?

GIVLAARI uses GalNAc-mediated hepatic delivery and monthly subcutaneous dosing. That places it closer to other GalNAc-siRNA products than to lipid nanoparticle products.

Product type	Delivery approach	Excipient implications
GIVLAARI	GalNAc-conjugated siRNA, subcutaneous	Simple aqueous formulation, sterile vial
Patisiran	Lipid nanoparticle, intravenous	Complex lipid excipient system and infusion handling
Other GalNAc-siRNA products	Ligand-conjugated siRNA, subcutaneous	Often simpler than lipid nanoparticles but dependent on oligonucleotide stability
Conventional injectable small molecules	Aqueous or cosolvent solution	More established generic and formulation pathways

Compared with lipid nanoparticle products, GIVLAARI has fewer formulation components and a simpler administration route. Compared with conventional injectables, it has greater active-ingredient complexity and more demanding analytical characterization.

What is the FDA regulatory status of GIVLAARI?

The FDA approved GIVLAARI in 2019 for adults with acute hepatic porphyria.[1] The approval was based on clinical evidence showing reductions in biochemical markers and attacks requiring healthcare intervention. The product is administered subcutaneously once monthly by weight-based dosing.

From an excipient perspective, future changes would likely require:

• pharmaceutical development and stability data;
• comparability to the approved product;
• assessment of local tolerability;
• container-closure qualification;
• updated extractables and leachables data where relevant;
• FDA review of the appropriate supplement or application pathway.

A material change to the active conjugate, dose concentration, or delivery device would carry a substantially higher regulatory burden than a supplier change for a compendial excipient supported by equivalence data.

Key Takeaways

• GIVLAARI uses a minimal excipient system consisting of water for injection, sodium hydroxide, and phosphoric acid.
• The principal commercial opportunity is in qualified sterile supply, fill-finish, container closure, and analytical services.
• Conventional excipient substitution is unlikely to create a strong standalone product because the active givosiran conjugate drives clinical performance and intellectual-property risk.
• GIVLAARI’s orphan-drug exclusivity began November 20, 2019 and generally runs through November 20, 2026.
• Givosiran has no conventional biosimilar pathway.
• Generic entry is more likely to involve a technically difficult ANDA or a differentiated 505(b)(2) product.
• The strongest IP barriers are likely to involve the siRNA sequence, GalNAc conjugation, ALAS1 silencing, and manufacturing methods.
• High-value lifecycle opportunities include prefilled syringes, lower-volume presentations, home administration, improved storage, and specialized analytical methods.
• Current Orange Book listings, patent-term adjustments, litigation, and settlement terms control the precise post-2026 entry analysis.

FAQs

Can a competitor use different excipients and still enter the GIVLAARI market?

Yes, but different excipients alone may not avoid patents covering givosiran’s sequence, conjugation structure, method of use, or manufacturing process.

Is GIVLAARI a candidate for an autoinjector?

Potentially, but an autoinjector would require assessment of dose volume, viscosity, injection force, device compatibility, human factors, and whether monthly administration can move safely from a clinical setting to the home.

Are sodium hydroxide and phosphoric acid patentable opportunities in GIVLAARI?

They are unlikely to provide meaningful standalone exclusivity because both are established pharmaceutical materials. Commercial differentiation would come from grade, sterility, impurity control, and supply reliability.

Could a lyophilized GIVLAARI product extend market exclusivity?

A lyophilized formulation could support separate composition or process claims if novel and nonobvious, but it would need to demonstrate a meaningful stability, logistics, or administration advantage.

What is the most defensible supplier position in the GIVLAARI ecosystem?

The strongest position is likely a validated combination of sterile excipient supply, oligonucleotide-compatible manufacturing, container-closure control, and analytical support rather than supply of a single conventional excipient.

References

1. U.S. Food and Drug Administration. (2019). GIVLAARI (givosiran) injection, prescribing information. FDA.

2. Alnylam Pharmaceuticals, Inc. (2019). GIVLAARI approval announcement and product information. Alnylam Pharmaceuticals.

3. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. FDA.

4. United States Patent and Trademark Office. (n.d.). Patent Center and Patent Examination Data System. USPTO.

5. Alnylam Pharmaceuticals, Inc. (2024). Annual report on Form 10-K. U.S. Securities and Exchange Commission.